文献速递临床免疫质量管理与危急值

荧光法即时检测AMH的分析性能、方法一致性与可用性双中心评估

Evaluation of a fluorescent-based point-of-care AMH assay: A bicentric assessment of analytical performance, method agreement, and usability.
PubMed 文献 · Clin Chim Acta · 2026-03-31

该双中心研究评估荧光法即时检测(POCT)AMH的分析性能、与常规实验室方法的一致性及可用性。结果显示POCT与常规方法强相关(Spearman r=0.967,p<0.0001),但存在比例偏倚,低浓度高估、中段偏差增大、高值接近等效。结论认为分析性能可接受,但接近临床决策阈值时需谨慎解读并实验室确认。

要点

  • POCT AMH与常规方法强相关(r=0.967),但存在比例偏倚(斜率0.925,截距0.213)。
  • 质控不精密度CV 4.1%–13.6%,正偏倚2.9%–17.8%,低浓度高估明显。
  • 接近临床决策阈值时需谨慎解读,必要时实验室确认。

核心结论

  • 荧光法POCT AMH分析性能可接受,与常规方法强相关且可用性良好,但方法间未 harmonization 前,接近临床决策阈值的结果需谨慎解读并实验室确认。

研究设计与样本

  • 双中心研究,在两家独立站点使用三个水平质控品评估精密度与正确度。
  • 方法比对采用304例匿名残余血清样本,覆盖临床相关AMH范围0.1–13 ng/mL。
  • 统计分析包括Passing-Bablok回归、Spearman相关和Bland-Altman分析,并用结构化问卷评估系统可用性。

主要发现

  • POCT AMH与常规实验室方法强相关(Spearman r=0.967,p<0.0001)。
  • Passing-Bablok回归斜率0.925、截距0.213,提示比例偏倚。
  • 质控不精密度CV 4.1%–13.6%,正偏倚2.9%–17.8%。
  • 呈现浓度依赖模式:低浓度高估、中段偏差增大、高值接近等效;Bland-Altman分析证实低至中AMH水平离散度更大。
  • 可用性评估显示易用性高、培训需求有限。

关键数值与推荐

  • 方法比对样本量304例,AMH范围0.1–13 ng/mL。
  • 相关性Spearman r=0.967,p<0.0001。
  • Passing-Bablok回归斜率0.925,截距0.213。
  • 质控不精密度CV 4.1%–13.6%,正偏倚2.9%–17.8%。

临床怎么用

  • POCT AMH可用于快速分散检测,但结果接近临床决策阈值时应谨慎解读。
  • 必要时对接近阈值的结果进行常规实验室方法确认。
  • 方法间 harmonization 未实现前,不宜直接互换POCT与实验室AMH结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-Müllerian hormone (AMH) measurement is central to ovarian reserve assessment but remains affected by inter-method variability among immunoassays. Point-of-care testing (POCT) enables rapid and decentralized AMH testing; however, independent evaluation of analytical performance and agreement with routine laboratory methods is required prior to clinical implementation. OBJECTIVE: To evaluate the analytical performance, method agreement, and usability of a fluorescent-based point-of-care AMH assay using a bicentric study design. METHODS: Analytical precision and trueness were assessed at two independent sites using three levels of quality control material. Method comparison was performed on 304 anonymized residual serum samples from routine laboratory requests, including infertility assessment, polycystic ovary syndrome (PCOS) investigation, in vitro fertilization (IVF) monitoring, and cancer surveillance, covering a clinically relevant AMH range (0.1-13 ng/mL). Statistical analyses included Passing-Bablok regression, Spearman correlation, and Bland-Altman analysis. System usability was assessed using a structured questionnaire. RESULTS: A strong correlation was observed between the POCT AMH assay and the routine laboratory method (Spearman r = 0.967, p < 0.0001). Passing-Bablok regression showed a slope of 0.925 and an intercept of 0.213, indicating a proportional bias. Quality control imprecision ranged from 4.1% to 13.6% (CV), with positive biases between 2.9% and 17.8%. A concentration-dependent pattern was observed, with overestimation at low concentrations, increased deviation in the mid-range, and near-equivalence at higher values. Bland-Altman analysis confirmed greater dispersion at low-to-mid AMH levels. Usability evaluation indicated high ease of use and limited training requirements. CONCLUSIONS: The fluorescent-based AMH POCT assay demonstrated acceptable analytical performance, strong correlation with a routine laboratory method, and favourable usability. However, until harmonisation across methods is achieved, cautious interpretation and confirmatory laboratory testing remain essential when results are close to clinical decision thresholds.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Khatib A, Gruson D, Azariouh I, et al. Evaluation of a fluorescent-based point-of-care AMH assay: A bicentric assessment of analytical performance, method agreement, and usability. Clin Chim Acta. 2026. PMID: 41933681. doi:10.1016/j.cca.2026.120998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。